Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Finished Goods (2016 - 2020)

United Therapeutics' Finished Goods history spans 11 years, with the latest figure at $43.8 million for Q1 2020.

  • For Q1 2020, Finished Goods fell 7.98% year-over-year to $43.8 million; the TTM value through Mar 2020 reached $43.8 million, down 7.98%, while the annual FY2019 figure was $43.2 million, 11.29% down from the prior year.
  • Finished Goods for Q1 2020 was $43.8 million at United Therapeutics, up from $43.2 million in the prior quarter.
  • Across five years, Finished Goods topped out at $62.2 million in Q3 2017 and bottomed at $37.3 million in Q2 2016.
  • The 5-year median for Finished Goods is $48.7 million (2018), against an average of $48.9 million.
  • The largest annual shift saw Finished Goods surged 65.15% in 2017 before it dropped 20.58% in 2018.
  • A 5-year view of Finished Goods shows it stood at $49.7 million in 2016, then increased by 12.47% to $55.9 million in 2017, then decreased by 12.88% to $48.7 million in 2018, then decreased by 11.29% to $43.2 million in 2019, then grew by 1.39% to $43.8 million in 2020.
  • Per Business Quant, the three most recent readings for UTHR's Finished Goods are $43.8 million (Q1 2020), $43.2 million (Q4 2019), and $45.0 million (Q3 2019).